About AEX AEX s principal business objectives are the identification, acquisition, exploration and development of gold properties in Greenland. The Corporation s principal asset is a 100% interest in the Nalunaq Project, an advanced exploration stage property with an exploitation license including the previously operating Nalunaq gold mine. The Corporation has a portfolio of gold assets covering 3,870km
2, the largest portfolio of gold assets in Southern Greenland covering the two known gold belts in the region. AEX is incorporated under the Canada Business Corporations Act and wholly owns Nalunaq A/S, incorporated under the Greenland Public Companies Act. Forward-Looking Information This press release contains forward-looking information within the meaning of applicable securities legislation, which reflects the Corporation s current expectations regarding future events and the future growth of the Corporation s business. In this press release there is fo
Notification of Transactions of Directors/Persons Discharging Managerial Responsibilities (PDMRs) TORONTO, ON / ACCESSWIRE / May 13, 2021 / AEX Gold Inc. (AIM: AEXG)(TSXV:AEX) announces that on May 13
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”
AEX Gold Inc.: AEX Board Changes
TORONTO, ON / ACCESSWIRE / April 29, 2021 / AEX Gold Inc. ( AEX or the Company ) (AIM:AEXG)(TSXV:AEX) is pleased to announce that Jaco Crouse has been appointed as a Director on the Company s Board of Directors, effective immediately. Mr. Crouse will be replacing Robert Ménard who has chosen to step down from his position after four years. Mr. Crouse currently holds the position of Chief Financial Officer ( CFO ) for the Company, following his appointment in January 2021, and will remain in this role.
Mr. Crouse has nearly 20 years experience in financial management, mine financial planning, business optimization and strategy development, and has already contributed significantly to the Company following his appointment as CFO.
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].”